In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020

Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa are being isolated from patient specimens with increasing frequency in Latin America and worldwide. The current study provides an initial description of the in vitro activity of imipenem/relebactam (IMR) against non-Morganellaceae Ente...

Full description

Bibliographic Details
Main Authors:	James A. Karlowsky, Sibylle H. Lob, Fakhar Siddiqui, Jacqueline Pavia, C. Andrew DeRyke, Katherine Young, Mary R. Motyl, Daniel F. Sahm
Format:	Article
Language:	English
Published:	Elsevier 2023-05-01
Series:	Brazilian Journal of Infectious Diseases
Subjects:	Imipenem/relebactam Non-Morganellaceae Enterobacterales Pseudomonas aeruginosa Latin America SMART Surveillance
Online Access:	http://www.sciencedirect.com/science/article/pii/S1413867023000351

Similar Items

AmpC induction by imipenem in Pseudomonas aeruginosa occurs in the absence of OprD and impacts imipenem/relebactam susceptibility
by: Shawn Freed, Jr, et al.
Published: (2024-11-01)

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
by: Leilei Wang, et al.
Published: (2023-06-01)

Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
by: Isabel Machuca, et al.
Published: (2024-11-01)

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
by: Dai Kurihara, et al.
Published: (2022-04-01)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
by: Soo Min Jang, et al.
Published: (2021-09-01)

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
by: Katherine Young, et al.
Published: (2019-07-01)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
by: Mervat Mashaly, et al.
Published: (2022-06-01)

Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis
by: Reza Abniki, MS, et al.
Published: (2024-01-01)

Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience
by: Cristiana Leanza, et al.
Published: (2024-07-01)

Review of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem-Vaborbactam and Imipenem-Relebactam in Carbapenemase Producing Klebsiella pneumoniae Isolates
by: Özlem AYDEMİR, et al.
Published: (2023-09-01)

Insights into the Rising Threat of Carbapenem-Resistant Enterobacterales and <i>Pseudomonas aeruginosa</i> Epidemic Infections in Eastern Europe: A Systematic Literature Review
by: Michal Piotrowski, et al.
Published: (2024-10-01)

Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018–2020
by: David W. Hilbert, et al.
Published: (2023-06-01)

Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant Enterobacterales Isolates
by: Jocelyn Qi-Min Teo, et al.
Published: (2023-06-01)

In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates
by: Dan Li, et al.
Published: (2023-12-01)

Comparison of the inoculum effect of in vitro antibacterial activity of Imipenem/relebactam and Ceftazidime/avibactam against ESBL-, KPC- and AmpC-producing Escherichia coli and Klebsiella pneumoniae
by: Xueting Wang, et al.
Published: (2023-12-01)

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae
by: FATMA SENA TÜRKDOĞAN, et al.
Published: (2024-12-01)

Can phenotypic methods accurately identify carbapenemase production in Morganellaceae?
by: Çisem Karaoğlu, et al.
Published: (2024-12-01)

Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres
by: Ryan K. Shields, et al.
Published: (2024-06-01)

Epidemiology and antimicrobial susceptibility profiles of Enterobacterales causing bloodstream infections before and during COVID-19 pandemic: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2018–2021
by: Yu-Lin Lee, et al.
Published: (2024-06-01)

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence
by: Pasquale Sansone, et al.
Published: (2024-05-01)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
by: Jaesh Naik, et al.
Published: (2023-01-01)

Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials
by: Qingxin Yang, et al.
Published: (2023-12-01)

Role of Relebactam in the Antibiotic Resistance Acquisition in <i>Pseudomonas aeruginosa</i>: In Vitro Study
by: Maria Paz Ventero, et al.
Published: (2023-11-01)

Mycobacterium abscessus skin and soft tissue infection following autologous fat grafting in Kurdistan treated with an antibiotic combination including Imipenem-Relebactam and Rifabutin
by: Alison J. Beech, et al.
Published: (2023-08-01)

Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient
by: Paolo Gaibani, et al.
Published: (2022-04-01)

First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion
by: Paul Laffont-Lozes, et al.
Published: (2024-10-01)

<i>Klebsiella pneumoniae</i> Susceptibility to Carbapenem/Relebactam Combinations: Influence of Inoculum Density and Carbapenem-to-Inhibitor Concentration Ratio
by: Maria V. Golikova, et al.
Published: (2022-06-01)

Evaluation of antibiofilm activity of cefiderocol alone and in combination with imipenem against Pseudomonas aeruginosa
by: Caterina Ferretti, et al.
Published: (2024-06-01)

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase
by: Krisztina M. Papp-Wallace, et al.
Published: (2023-05-01)

The importance of meropenem resistance, rather than imipenem resistance, in defining carbapenem-resistant Enterobacterales for public health surveillance: an analysis of national population-based surveillance
by: Chiaki Ikenoue, et al.
Published: (2024-02-01)

METALLO-ß-LACTAMASE PRODUCTION IN IMIPENEM RESISTANT STRAINS OF PSEUDOMONAS AERUGINOSA
by: Fazle Bari, et al.
Published: (2019-06-01)

Difficult-to-Treat <i>Pseudomonas aeruginosa</i> Infections in Critically Ill Patients: A Comprehensive Review and Treatment Proposal
by: Pablo Vidal-Cortés, et al.
Published: (2025-02-01)

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam
by: Min Seo Kang, et al.
Published: (2024-06-01)

Prevalence of Imipenemase and Verona Integron-Encoded Metallo-β-Lactamase in Imipenem-Resistant Pseudomonas aeruginosa
by: Wanutsanun Tunyapanit, et al.
Published: (2021-09-01)

Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa – Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020
by: Sibylle H. Lob, et al.
Published: (2022-12-01)

Imipenem/cilastatin encapsulation in UIO-66-NH2 carrier as a new strategy for combating imipenem-resistant Pseudomonas aeruginosa isolates
by: Shakila Baei Lashaki, et al.
Published: (2025-05-01)

Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant <i>Pseudomonas aeruginosa</i>
by: Sara Mahmoud Farhan, et al.
Published: (2021-11-01)

Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015‒2020
by: Mark G. Wise, et al.
Published: (2023-05-01)

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing
by: Małgorzata Brauncajs, et al.
Published: (2024-03-01)

In Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa Collected in Turkey and the Middle East: ATLAS Global Surveillance Program 2018-2022
by: Meredith Hackel, et al.
Published: (2024-12-01)